The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 3 March 2026•Updated 4 March 2026•

1 min read

Moderna Settles Patent Dispute for $2.25 Billion; Shares Jump 10%

Key Facts

1Moderna's stock surged by more than 10% following a deal to resolve a patent dispute.

3 months ago

Version History

Version 13 months ago

What changed: Updated the story to include the $2.25 billion settlement amount, the specific legal counterparties (Arbutus and Genevant), and the specific vaccines covered by the agreement.

Moderna (MRNA) shares surged by 10% following the announcement of a comprehensive settlement to resolve long-standing global patent infringement lawsuits. The company agreed to pay up to $2.25 billion to settle disputes with Arbutus Biopharma and Genevant Sciences over the use of lipid nanoparticle (LNP) delivery technology. This agreement effectively resolves all legal challenges related to Moderna's Spikevax COVID-19 vaccine and its mRESVIA RSV vaccine. By finalizing these terms, the company has removed a significant legal overhang that had previously weighed on its market valuation. Investors reacted positively to the clarity provided by the settlement, viewing it as a pivotal step toward securing the company’s intellectual property framework. The resolution allows Moderna to refocus its resources on advancing its mRNA-based clinical pipeline and long-term strategic growth without the distraction of ongoing litigation.